Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPRANO: High-dose Pulsatile Sorafenib
NCT02636426Phase 1Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sorafenib in solid tumor (advanced stage), sponsored by Amsterdam University Medical Center. Primary endpoints: Maximum Tolerated Plasma AUC0-12h at 42 days and Safety and Tolerability at 42 days. Started Sep 2015; status: completed.
02
Drugs
sorafenib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02636426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636426.